TargetAMD examination © TargetAMD

Target AMD: Transposon-based, targeted ex vivo gene therapy for the treatment of age-related macular degeneration (AMD)

funding programme

7th Research Framework Program

client

Krankenanstalt Rudolfsstiftung

duration

November 2012 - October 2016

Age-related macular degeneration (AMD) is a disease of the light-sensitive part of the eye (retina), which is responsible for vision. It is one of the main causes of blindness in older people and is referred to as a "time bomb" in society due to the ageing population. The project has brought a better quality of life for patients and has opened up novel products for clinical applications of specific gene therapy.

Health, Social Services, Sports

TargetAMD Logo

EuroVienna's services

Financial management:

Funding settlements and the administration involved in project implementation are time-consuming. The applicable regulations are often not comparable with the familiar rules of the Austrian financial administration, especially as all countries of the European Union can obtain funding.  EuroVienna has ensured that all funding regulations of the 7th Research Framework Programme have been complied with in the course of project implementation and accounting in order to optimize the financial benefits of TargetAMD:

  • Recording the project costs to be invoiced;
  • Ongoing monitoring of the project budget;
  • Preparation of documents and creation of financial reports;
  • Reporting to the reporting tool.
TargetAMD Laboratory © TargetAMD

Project summary

Age-related macular degeneration (AMD) is a disease of the light-sensitive part of the eye (retina), which is responsible for vision. AMD is one of the main causes of blindness in older people and is described as a "time bomb" in society due to the ageing population. The aim of the project was to develop a transposon-based gene therapy for the exudative form of age-related macular degeneration (AMD) and to translate the treatment into the first clinical trial (phase Ib/IIa) in Europe. The diverse consortium consisted of specialists offering a broad range of experience and knowledge in the field of AMD pathology and treatment with key competencies in genetic engineering, molecular and cell biology, in vivo modeling, ophthalmic surgery, clinical trials, quality control and GMP-compliant production.

Results and impact

TargetAMD brought together an interdisciplinary team of outstanding scientists from eight European countries. Five companies, three academic partners, five university hospitals and universities represented the international consortium of 13 partners.

TargetAMD has significantly improved the quality of life of AMD patients, highlighted the synergistic power of academic, clinical and industry collaboration in the scientific arena and opened up new markets for novel products for clinical applications of transposon-based gene therapy.

Eye close-up © Pexels/Pixabay

Project partners:

  • Université de Genève (UNIGE), Service d'Ophtalmologie (Switzerland)
  • Rheinisch‐Westfälische Technische Hochschule Aachen (Germany)
  • Max-Delbrück-Centrum für Molekulare Medizin (Germany)
  • Paul-Ehrlich-Institut für Impfstoffe und biomedizinische Arzneimittel (Germany)
  • Universidad de Navarra (Spain)
  • IGEA SPA (Italy)
  • UD-GenoMed Medical Genomic Technologies Kft. (Hungary)
  • Centre national de la recherche scientifique (France)
  • 3P Biopharmaceuticals S.L. (France)
  • Genosafe SAS (France)
  • Krankenanstalt Rudolfstiftung (Austria)
  • Novartis Pharma GmbH (Germany)
  • Universitätsklinikum Aachen Klinik für Augenheilkunde (Germany)
  • Hotswap Stockholm AB (Sweden)
  • Stichting Amsterdam Biotherapeutics Unit (Netherlands)

Project area:

  • Austria, France, Germany, Hungary, Italy, Netherlands, Spain, Sweden, Switzerland

Website(s):

    https://www.targetamd.eu/

teilen

Teilen